4D Molecular Therapeutics (FDMT) Operating Leases (2021 - 2026)

4D Molecular Therapeutics (FDMT) has reported Operating Leases for 6 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 17.19% year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $15.0 million (down 17.19% YoY), while the FY2025 annual figure was $15.8 million, down 16.6% from the prior year.
• Operating Leases declined to $15.0 million in Q1 2026 per FDMT's latest filing, from $15.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $19.7 million in Q3 2024 and bottomed at $10.5 million in Q2 2024.
• Historically, Operating Leases has averaged $14.6 million across 5 years, with a median of $14.4 million in 2022.
• Annual changes were most pronounced in 2025 — Operating Leases surged 65.93% — and 2026, when it slipped 17.19%.
• 4D Molecular Therapeutics' Operating Leases stood at $13.5 million in 2022, then declined by 14.46% to $11.5 million in 2023, then surged by 64.63% to $19.0 million in 2024, then fell by 16.6% to $15.8 million in 2025, then decreased by 4.88% to $15.0 million in 2026.
• Business Quant data shows FDMT's Operating Leases at $15.0 million in Q1 2026, $15.8 million in Q4 2025, and $16.6 million in Q3 2025.